Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (French: Conseil d'examen du prix des médicaments brevetés) is a federal quasi-judicial regulatory and reporting agency in Canada with a mandate to protect consumers by ensuring that the prices of patented medication charged by manufacturers of patented drugs are not excessive. The board does this through its role as a regulator, and through its reporting on trends, research and development in the pharmaceutical industry.[2]

Patented Medicine Prices Review Board
Conseil d'examen du prix des médicaments brevetés
Agency overview
Formed1987 (1987)
JurisdictionCanada
HeadquartersOttawa
Employees74
Annual budgetCA$10.3 million[1]
Minister responsible
Agency executives
  • Mitchell Levine, Chairperson
  • Mélanie Bourassa Forcier, Vice-chairperson
  • Douglas Clark, Executive Director
Key document
  • Patent Act
Websitewww.canada.ca/en/patented-medicine-prices-review.html

The board investigates, reviews and negotiates the price of individual drugs that are still under patent and which have no generic substitutes. It board establishes the maximum prices that can be charged in Canada for patented drugs.[3][4]

Accountability

The board is accountable to Parliament through the minister of health, the elected official responsible for the health portfolio. Under sections 89 and 100 of the Patent Act, the board produces an annual report submitted to the minister, who tables it in the House of Commons.[5][6]

Background

Bill C-22, which was passed in 1987, extending the "period of patent protection before compulsory licensing could be possible"[Notes 1] and established the federal Patented Medicine Prices Review Board. The board determines a maximum price for individual drugs through a review process, and negotiates "voluntary compliance agreements" with drug companies to ensure that "manufacturer prices are within justification, and [are] not excessive".[6]:93

Annual reports

According to their annual report for the fiscal year 2017, there were 1,391 patented medicines for human use that were reported, which included 80 new medicines. By December 31, 2017, there were 14 voluntary compliance undertakings accepted.[7][8] Patented medicines represented 61.5% of the total medicine sales in Canada in 2017 up from 60.8% in 2016.[7]

Notes
  1. According to the June 2001 article published in Health Affairs, since 1969, an amendment to the 1923 Patent Act allowed manufacturers to import a patented drug, if they paid a royalty to the patent holders. Bill C-22 extended that period of patent protection.

References
  1. "GC InfoBase". www.tbs-sct.gc.ca. Retrieved 2020-10-16.
  2. "GC InfoBase". www.tbs-sct.gc.ca. Retrieved 2020-10-16.
  3. "Prescription Drug Prices in Canada: What Are the Lessons for the U.S.?". AARP International. Washington, DC.Prescription drug prices in the United States
  4. "Facing crackdown in Canada, drugmakers offered billions in price cuts: Delayed rules would change countries Canada compares its prices to, dropping U.S." Thomson Reuters via CBC. February 6, 2019. Retrieved February 6, 2019.
  5. "ANNUAL REPORT 2018" (PDF).
  6. Menon, Devidas (June 2001). "Pharmaceutical Cost Control in Canada: Does It Work?" (PDF). Health Affairs. 20: 1–12. doi:10.1377/hlthaff.20.3.92. PMID 11585186. Retrieved February 6, 2019.
  7. "Annual Report 2017". PMPRB. 2018-07-12. Retrieved 2019-02-07.
  8. 1998. Report of the Patented Medicine Prices Review Board. Road Map for the Next Decade Ottawa, Ontario. 36pp.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.